ATRX and cancer: Mutations of histone chaperones DAXX and ATRX reduce the level of histone variant H3.3 (92) and active the ALT pathway in telomerase-negative cancers, suggesting that the incorporation of H3.3 is necessary for telomere maintenance (80, 131–133).